Goodwin’s Life Sciences team advised Blueprint Medicines (NASDAQ: BPMC), on its underwritten public offering of 4,259,259 shares of its common stock at a public offering price of $81.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be approximately $325.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases.
The Goodwin team was led by partners Danielle Lauzon and Kingsley Taft, and included associate Yasin Akbari.
For more information on the offering, please read the press release.